Stockhead’s Top 10 at 11, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.



Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

Code Description Last % Volume MktCap
AT1 Atomo Diagnostics 0.052 93% 8,004,823 $17,258,462
MCT Metalicity Limited 0.0025 25% 3,721,236 $8,970,108
NVQ Noviqtech Limited 0.005 25% 1,210,000 $5,237,781
1AD Adalta Limited 0.03 20% 12,475,013 $13,145,102
88E 88 Energy Ltd 0.006 20% 24,865,026 $125,620,313
AL8 Alderan Resource Ltd 0.006 20% 4,000,000 $5,534,307
OAU Ora Gold Limited 0.006 20% 100,000 $28,700,004
RNX Renegade Exploration 0.007 17% 476,928 $6,010,343
ALM Alma Metals Ltd 0.008 14% 6,250 $7,798,006
POS Poseidon Nick Ltd 0.008 14% 740,223 $25,994,743
Wordpress Table Plugin

Atomo Diagnostics (ASX:AT1) has announced it’s secured ~$970,000 worth of orders from Viatris Healthcare Pty Ltd for its HIV Self-Tests, manufactured by Atomo under the Mylan brand for supply to a number of Low- and Middle-Income Countries (LMICs) with manufacture during H2 FY24.

Metalicity (ASX:MCT) says drilling approvals at its 80% owned Yundamindra Gold Project (20% owned by JV partner Nex Metals Exploration (ASX:NME) have been lodged for the first drilling program in over a decade. MCT says following favourable Wardens Court decisions regarding the Yundamindra tenements the company has been undertaking extensive internal and external review of all historical data and activities at the highly prospective gold project.

AdAlta (ASX:1AD)  says key results from its Phase I extension study of lead asset AD-214 have achieved the critical milestones including positively answered key partnering discussion questions from pharma companies, while establishing the safety and tolerability of the planned Phase II dose.

AD-214 is being developed for fibrotic diseases including the debilitating and fatal disease, Idiopathic Pulmonary Fibrosis (IPF) and is now ready to progress to Phase II clinical studies.



Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

Code Company Price % Volume Market Cap
ASQ Australian Silica 0.016 -65% 158,087 $12,965,577
CTT Cettire 3.5 -25% 4,067,078 $1,776,570,105
TSL Titanium Sands Ltd 0.007 -22% 32,524 $17,943,572
EDE Eden Inv Ltd 0.002 -20% 380,375 $9,195,678
GCM Green Critical Min 0.005 -17% 45,186 $6,819,510
REY REY Resources Ltd 0.085 -15% 900 $21,168,754
ZNO Zoono Group Ltd 0.035 -13% 3,000 $8,547,096
DDR Dicker Data Limited 10.63 -12% 18,751,041 $2,173,303,320
SGA Sarytogan 0.2 -11% 129,141 $17,313,729
ADG Adelong Gold Limited 0.004 -11% 4,350,500 $3,230,950
Wordpress Table Plugin


Dicker Data (ASX:DDR) has announced founder, chairman and CEO has David Dicker has sold down ~8.3 million shares  representing ~10.2% of the company’s issued capital due to a recent divorce settlement and restructuring of his portfolio.

The sale was undertaken at a price of $10.90 per share by way of an underwritten block trade equating to ~$90.47 million.

DDR says its free float is expected to increase from ~36% to 46% and Dicker has entered into a 6-month escrow on his remaining shareholding.

Biotech developing antimicrobial solutions Zoono Group (ASX:ZNO) has entered into an exclusive agency agreement with OSY Group Limited (OSY) to promote the sale of Zoono products for he food supply chain sector. ZNO says based in Manchester, England OSY is a leading-edge provider of sustainable technologies in the hygiene technology sector.